Skip to main content

Peer Review reports

From: Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

Original Submission
27 Sep 2022 Submitted Original manuscript
10 Oct 2022 Reviewed Reviewer Report - Petros Christopoulos
23 Oct 2022 Reviewed Reviewer Report
24 Nov 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 2
24 Nov 2022 Submitted Manuscript version 2
29 Nov 2022 Reviewed Reviewer Report - Petros Christopoulos
16 Dec 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 3
16 Dec 2022 Submitted Manuscript version 3
Publishing
13 Jan 2023 Editorially accepted
24 Feb 2023 Article published 10.1186/s12916-023-02738-5

You can find further information about peer review here.

Back to article page